Sponsor study identifier
interventional
30
1 country
1
Study Start
October 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2009
Actual (reported)Study Completion
January 2009
Actual (reported)The purpose of the study is to assess the safety, efficacy and tolerability of Clobetasol propionate foam in subjects with chronic dermatitis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2008
Date type not reportedThis date has not been verified as actual or estimated.
January 2009
Actual (reported)January 2009
Actual (reported)January 22, 2009
Actual (reported)January 26, 2009
Actual (reported)September 28, 2010
Actual (reported)Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score
Proportion of Subjects with at least a 1-Grade Improvement from Baseline to Day 15 In Investigator's Static Global Assessment Score (ISGA) - Chronic Hand Dermatitis Please note that the proportion of participants is being reported as a percentage of participants. ISGA grades: Score = 0 (Clear) Score = 1 (Almost Clear) Score = 2 (Mild) Score = 3 (Moderate) Score = 4 (Severe)
Baseline, Day 15
Proportion of Subjects Who Achieve at Least a 1-grade Improvement Based on the ISGA at Day 8.
Baseline, Day 8
Change in Subject's Visual Analogue Assessment Scale
Baseline, Day 8
Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips
Baseline, Day 15
Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips
Baseline, Day 8
Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline - Fingers
Baseline, Day 15
All subjects receive clobetasol propionate
Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Physicians Skin Care
Louisville, Kentucky, 40217, United States
Kircik LH, Tropmann C. Treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% EF foam: results from an open-label study. J Drugs Dermatol. 2011 Dec;10(12):1398-402.
Open label study
GSK Clinical Trials
GlaxoSmithKline
30 participants (actual enrollment reported by the registry).
First Submitted
January 22, 2009
First Posted
January 26, 2009
Study Start
October 2008
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
January 2009
Actual (reported)Study Completion
January 2009
Actual (reported)Last Updated
October 3, 2012
Results First Posted
September 28, 2010
Record last verified: 2012-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: